| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The molecular targets of Bancroftinone are not fully characterized. As a phenolic compound related to eugenol, it may exhibit antioxidant activity through free radical scavenging. Its anti-inflammatory activity is likely mediated through inhibition of pro-inflammatory mediators such as NO, TNF-α, and IL-6. Its antimicrobial activity suggests interactions with bacterial cell membranes or essential enzymes. Further research is needed to identify specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies of Bancroftinone have demonstrated antioxidant, anti-inflammatory, and antimicrobial activities. However, specific potency data such as IC₅₀ values are not detailed in the available literature. The compound is primarily a research tool for studying the pharmacology of phenolic natural products related to eugenol. Its in vitro applications include studies of oxidative stress, inflammation, and infectious diseases.
|
| ln Vivo |
Specific in vivo activity data for Bancroftinone are not available in the consulted sources. As a natural compound related to eugenol, it may have potential in vivo efficacy in models of inflammation, oxidative stress, and infection. However, systematic in vivo studies have not been reported. Further research is needed to evaluate its pharmacokinetics and efficacy.
|
| Enzyme Assay |
Typical in vitro assays for Bancroftinone include DPPH and ABTS radical scavenging assays for antioxidant activity. Anti-inflammatory activity is assessed by measuring NO production in LPS-stimulated macrophages using the Griess assay. Antimicrobial activity is assessed by broth microdilution methods to determine MIC values against bacterial and fungal strains. These protocols are standard for evaluating the biological activities of phenolic compounds.
|
| Cell Assay |
Cellular assays for Bancroftinone typically involve treating macrophages (e.g., RAW 264.7) with the compound at concentrations ranging from 1-100 µM for 24-48 hours. Inflammatory markers such as NO, TNF-α, and IL-6 are measured by ELISA or Griess assay. ROS levels are measured using fluorescent probes. Cell viability is assessed by MTT assay. These cell-based systems allow for analysis of the compound's mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for Bancroftinone are not detailed in the available literature. For anti-inflammatory studies, typical animal models include carrageenan-induced paw edema or LPS-induced systemic inflammation. For antioxidant studies, models of oxidative stress are used. However, such studies have not been reported for this specific compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Bancroftinone are limited. As a phenolic compound related to eugenol, it would be expected to have good oral bioavailability. Eugenol is known to be absorbed and metabolized by conjugation reactions. However, detailed ADME parameters for Bancroftinone are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for Bancroftinone are limited. As a natural phenolic compound related to eugenol, it is generally considered to have low toxicity at dietary levels. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Bancroftinone is an aromatic ketone.
Bancroftinone is a natural product structurally related to eugenol, with potential antioxidant, anti-inflammatory, and antimicrobial activities. It is a research compound for studying the pharmacology of phenolic natural products. It is not approved for any clinical indication. |
| Molecular Formula |
C11H14O4
|
|---|---|
| Molecular Weight |
210.23
|
| Exact Mass |
210.089
|
| CAS # |
14964-98-8
|
| PubChem CID |
11287272
|
| Appearance |
White to off-white solid
|
| Melting Point |
44–45 °C
|
| LogP |
1.92
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
229
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1=C(C(C)=O)C(=CC(=C1C)OC)O
|
| InChi Key |
DUTVTRPNMVUOIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H14O4/c1-6-9(14-3)5-8(13)10(7(2)12)11(6)15-4/h5,13H,1-4H3
|
| Chemical Name |
1-(6-hydroxy-2,4-dimethoxy-3-methylphenyl)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (475.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7567 mL | 23.7835 mL | 47.5670 mL | |
| 5 mM | 0.9513 mL | 4.7567 mL | 9.5134 mL | |
| 10 mM | 0.4757 mL | 2.3783 mL | 4.7567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
